Home > Insider Trading > Filing (0001493152-22-023511)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1357459	Palisade Bio Inc.	PALI	Biological Products, (No Disgnostic Substances) (2836)	522007292

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1850921	Thomas Hallam	7750 El Camino Real, Suite 5200 Carlsbad, CA 92009	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.01	Acquisiton	2022-08-16	40,000	$0.25	57,592	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series 1 Common Stock Purchase Warrant	Acquisiton	2022-08-16	40,000	$0.00	40,000	$0.25
Common Stock	Series 2 Common Stock Purchase Warrant	Acquisiton	2022-08-16	40,000	$0.00	40,000	$0.25

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
40,000		2023-08-16	No	4	P	Direct
40,000		2027-08-16	No	4	P	Direct

Footnotes

Represents common shares underlying 40,000 Units of Issuer purchased by Reporting Person ("Units") in Underwritten Offering with each Unit containing (i) one share of common stock, (ii) one Series 1 Warrant and (iii) One Series 2 Warrant at a price per Unit of $0.25.
Represents Series 1 Common Stock Purchase Warrants received as part of the Units purchased by Reporting Person. The Series 1 Warrants are exercisable upon receipt of stockholder approval per Nasdaq rules, which has not been obtained as of the date of this Form 4.
Represents Series 2 Common Stock Purchase Warrants received as part of the Units purchased by Reporting Person. The Series 2 Warrants are exercisable upon receipt of stockholder approval per Nasdaq rules, which has not been obtained as of the date of this Form 4.